Docetaxel Actavis
Taxoid Chemotherapy for Breast, Lung, Prostate, Gastric and Head/Neck Cancers
Quick Facts About Docetaxel Actavis
Key Takeaways
- Docetaxel Actavis is a taxoid chemotherapy drug used to treat breast, lung, prostate, gastric, and head/neck cancers, either alone or in combination with other anticancer agents.
- It is administered as an intravenous infusion over approximately one hour, typically once every three weeks in a hospital or clinic setting.
- Premedication with oral corticosteroids (dexamethasone) is mandatory before each cycle to reduce the risk of severe allergic reactions and fluid retention.
- The most common side effects include low blood cell counts (neutropenia), hair loss, nausea, mouth sores, diarrhoea, fatigue, and peripheral neuropathy.
- Docetaxel must not be used during pregnancy or breastfeeding, and both men and women must use effective contraception during and after treatment.
What Is Docetaxel Actavis and What Is It Used For?
Docetaxel Actavis contains the active substance docetaxel, a semi-synthetic compound originally derived from the needles of the European yew tree (Taxus baccata). It belongs to the taxoid class of anticancer drugs, which also includes paclitaxel. Docetaxel was first approved for medical use in the mid-1990s and has since become one of the most widely used chemotherapy agents worldwide, listed on the World Health Organization (WHO) Model List of Essential Medicines.
Docetaxel works by promoting the assembly of tubulin into stable microtubules while simultaneously preventing their disassembly. Microtubules are essential structural components of cells that play a critical role in cell division (mitosis). By stabilising these structures and preventing their normal dynamic behaviour, docetaxel effectively blocks cell division, ultimately leading to programmed cell death (apoptosis). This mechanism of action makes it particularly effective against rapidly dividing cancer cells.
Docetaxel Actavis is prescribed for the treatment of several types of cancer. In advanced breast cancer, it can be used as a single agent or in combination with doxorubicin, trastuzumab, or capecitabine, depending on the specific clinical situation and hormone receptor status. For early-stage breast cancer that has or has not spread to the lymph nodes, docetaxel is commonly used in the TAC regimen (combined with doxorubicin and cyclophosphamide), which has been shown in large randomised controlled trials to significantly improve disease-free survival.
In non-small cell lung cancer (NSCLC), docetaxel may be administered either as monotherapy in the second-line setting (after failure of prior platinum-based chemotherapy) or in combination with cisplatin as first-line treatment. The TAX 326 study and other landmark trials demonstrated significant improvements in overall survival with docetaxel-containing regimens in NSCLC.
For metastatic castration-resistant prostate cancer, docetaxel combined with prednisone or prednisolone remains a cornerstone of treatment. The TAX 327 trial established docetaxel as the first chemotherapy agent to demonstrate a survival benefit in this setting, with a median overall survival improvement of approximately 2.5 months compared to mitoxantrone. Additionally, docetaxel is used for gastric adenocarcinoma (in combination with cisplatin and 5-fluorouracil) and squamous cell carcinoma of the head and neck (with cisplatin and 5-fluorouracil as induction chemotherapy before definitive local treatment).
What Should You Know Before Taking Docetaxel Actavis?
Contraindications
Docetaxel Actavis must not be used in several specific situations. Your oncologist will thoroughly evaluate your medical history and current health status before initiating treatment. The following are absolute contraindications:
- You have a known severe hypersensitivity (allergy) to docetaxel or to polysorbate 80, which is one of the excipients in the formulation
- Your baseline neutrophil count is below 1,500 cells per cubic millimetre (cells/mm³), indicating dangerously low white blood cell levels
- You have severe hepatic (liver) impairment, as docetaxel is primarily metabolised in the liver and impaired liver function significantly increases the risk of severe, potentially fatal toxicity
Before each treatment cycle, your healthcare team will perform blood tests to ensure that your blood cell counts and liver function are adequate to safely receive docetaxel. These tests are non-negotiable and form a critical part of the safety monitoring protocol. If your white blood cell count is too low, your treatment may be delayed until counts recover to safe levels.
Warnings and Precautions
Docetaxel is a potent chemotherapy agent with significant potential toxicities. Understanding these warnings is essential for safe treatment. Your healthcare team will monitor you closely, but it is equally important that you report any unusual symptoms promptly.
Gastrointestinal toxicity: Contact your doctor, pharmacist, or nurse immediately if you develop abdominal pain or tenderness, diarrhoea, rectal bleeding, blood in the stool, or fever. These symptoms can be early signs of serious gastrointestinal damage, including colitis and intestinal perforation, which can be life-threatening. Early recognition and treatment are critical to preventing severe outcomes.
Visual disturbances: If you experience any problems with your vision, particularly blurred vision, you should have your eyes and vision examined promptly. Docetaxel has been associated with cystoid macular oedema (swelling of the retina), which can impair visual acuity. In most cases, this resolves after discontinuation of therapy, but early detection is important.
Hypersensitivity reactions: Allergic reactions can occur during or shortly after the infusion. If you have previously experienced an allergic reaction to paclitaxel (another taxoid), you may be at increased risk for a reaction to docetaxel, potentially of greater severity. Your medical team will monitor you closely during each infusion and has emergency medications available.
Cardiac concerns: Inform your doctor if you have existing heart problems. Heart failure has been reported in patients receiving docetaxel, particularly in combination with trastuzumab or anthracyclines such as doxorubicin. Cardiac monitoring may be performed during your treatment course.
Pulmonary toxicity: If you develop acute or worsening lung symptoms such as fever, shortness of breath, or persistent cough, inform your healthcare team immediately. Interstitial lung disease, pneumonitis, and pulmonary fibrosis have been reported with docetaxel. In some cases, treatment may need to be discontinued permanently.
Premedication with corticosteroids: You will be prescribed oral corticosteroid premedication (typically dexamethasone 8 mg twice daily for three days, starting one day before each docetaxel infusion). This is a mandatory step that significantly reduces the incidence and severity of hypersensitivity reactions and fluid retention. Never skip your premedication doses.
Severe skin reactions: Serious skin conditions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalised exanthematous pustulosis (AGEP) have been reported. Symptoms of SJS/TEN include blistering, peeling, or bleeding of the skin (including lips, eyes, mouth, or genitals) with or without rash, possibly accompanied by flu-like symptoms. AGEP symptoms include a red, scaly, widespread rash with bumps under swollen skin, accompanied by fever. If you develop any severe skin reaction, contact your doctor immediately.
TLS is a potentially serious condition that may occur when cancer cells break down rapidly, releasing their contents into the bloodstream. Symptoms include seizures, reduced urine output or dark-coloured urine, and irregular heartbeat. If you have elevated uric acid levels or kidney problems before treatment, your doctor will implement preventive measures and monitor you closely.
Alcohol content: Docetaxel Actavis contains ethanol (alcohol) at approximately 40% weight/volume. The alcohol content varies by vial size (for example, the 1 ml vial contains approximately 400 mg ethanol, equivalent to about 10 ml of beer). This is clinically relevant for patients with a history of alcohol dependence, liver disease, epilepsy, or those taking medications that interact with alcohol. The alcohol content may also affect your ability to drive or operate machinery following infusion.
Pregnancy and Breastfeeding
Docetaxel poses significant risks to reproductive health and fetal development. It is essential to understand these risks before starting treatment.
- Pregnancy: Docetaxel must NOT be used during pregnancy unless the potential benefit clearly outweighs the risk to the foetus and the physician has specifically deemed it necessary. Docetaxel can cause serious harm to the developing baby.
- Contraception for women: Women of childbearing potential must use effective contraception during treatment and for at least 2 months after the last dose of docetaxel. If you become pregnant during treatment, inform your doctor immediately.
- Contraception for men: Male patients must use effective contraception during treatment and for at least 4 months after the last dose. Men should seek counselling regarding sperm banking before starting treatment, as docetaxel may affect male fertility.
- Breastfeeding: You must NOT breastfeed during treatment with docetaxel. It is unknown whether docetaxel passes into breast milk, and a risk to the nursing infant cannot be excluded.
Driving and Operating Machinery
The alcohol content in Docetaxel Actavis, combined with potential side effects such as fatigue, dizziness, and neuropathy, may impair your ability to drive or operate machinery. You are personally responsible for assessing whether you are fit to drive after treatment. Do not drive or use machines if you experience any side effects that could impair your concentration or reaction time. Discuss this with your healthcare team if you are unsure.
How Does Docetaxel Actavis Interact with Other Drugs?
Drug interactions with docetaxel are primarily mediated through the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver, which is the main pathway for docetaxel metabolism. Drugs that inhibit or induce CYP3A4 can significantly alter docetaxel plasma concentrations, leading to either increased toxicity or reduced efficacy. It is crucial that your oncologist is aware of all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins.
The alcohol content in Docetaxel Actavis may also interact with other medications. Central nervous system depressants, sedatives, anxiolytics, and certain antihistamines may have their effects potentiated by the ethanol component. Always disclose your complete medication list to your healthcare team.
Major Interactions
| Drug / Class | Interaction Type | Clinical Significance |
|---|---|---|
| Ketoconazole | Strong CYP3A4 inhibitor | Can increase docetaxel exposure by approximately 50%, significantly raising the risk of severe neutropenia and other toxicities |
| Itraconazole | Strong CYP3A4 inhibitor | Similar to ketoconazole; concomitant use requires dose adjustment or avoidance |
| Ritonavir / HIV protease inhibitors | Strong CYP3A4 inhibitor | Substantially increases docetaxel levels; dose reduction or alternative antiviral therapy may be necessary |
| Erythromycin / Clarithromycin | Moderate CYP3A4 inhibitor | Can moderately increase docetaxel plasma concentration; monitor closely for toxicity |
| Cyclosporine | CYP3A4 inhibitor / P-glycoprotein substrate | May increase docetaxel exposure; therapeutic drug monitoring recommended |
Minor Interactions and Combination Therapy
| Drug / Class | Interaction Type | Clinical Significance |
|---|---|---|
| Cisplatin | Approved combination partner | Used together in lung, gastric, and head/neck cancers; additive nephrotoxicity and myelosuppression require close monitoring |
| Doxorubicin | Approved combination partner | TAC regimen for breast cancer; cumulative cardiotoxicity risk; cardiac monitoring recommended |
| Trastuzumab | Approved combination partner | For HER2-positive breast cancer; increased risk of heart failure; regular cardiac function assessment required |
| Rifampicin | Strong CYP3A4 inducer | May significantly reduce docetaxel plasma levels, potentially compromising efficacy; avoid concomitant use if possible |
| St John’s Wort | CYP3A4 inducer | Can reduce docetaxel levels; herbal supplements should be disclosed and avoided during treatment |
What Is the Correct Dosage of Docetaxel Actavis?
Docetaxel Actavis is exclusively administered by trained healthcare professionals in a hospital or oncology clinic. The dose is individualised based on your body surface area (BSA), which is calculated from your height and weight and expressed in square metres (m²). Your oncologist will determine the appropriate dose based on the specific cancer type, treatment protocol, your overall health, and how you respond to previous cycles.
Adults
| Cancer Type | Typical Dose | Schedule | Combination |
|---|---|---|---|
| Breast cancer (advanced) | 75–100 mg/m² | Every 3 weeks | Alone, or with doxorubicin, trastuzumab, or capecitabine |
| Breast cancer (adjuvant, TAC) | 75 mg/m² | Every 3 weeks × 6 cycles | With doxorubicin and cyclophosphamide |
| Non-small cell lung cancer | 75 mg/m² | Every 3 weeks | Alone or with cisplatin |
| Prostate cancer | 75 mg/m² | Every 3 weeks | With prednisone or prednisolone |
| Gastric adenocarcinoma | 75 mg/m² | Every 3 weeks | With cisplatin and 5-fluorouracil |
| Head and neck cancer | 75 mg/m² | Every 3 weeks | With cisplatin and 5-fluorouracil (induction) |
Children
Docetaxel is not routinely used in children. There is limited clinical experience with docetaxel in paediatric patients. The safety and efficacy of docetaxel in children and adolescents under 18 years of age have not been established for the approved indications. In rare cases where docetaxel may be considered for a paediatric patient with a specific tumour type, the treatment would be managed in a specialised paediatric oncology centre with appropriate dose adjustments and intensive monitoring.
Elderly
No specific dose adjustments are required for elderly patients based on age alone. However, elderly patients are generally more susceptible to the adverse effects of chemotherapy, including myelosuppression, fatigue, and peripheral neuropathy. Your oncologist will consider your overall fitness (performance status), organ function, and comorbidities when determining the appropriate dose. In some cases, a lower starting dose or dose reduction may be warranted to reduce the risk of severe toxicity while maintaining therapeutic efficacy.
Dose Modifications
Your oncologist may modify your docetaxel dose or delay treatment cycles based on how you respond to therapy. Dose reductions are commonly implemented for:
- Severe neutropenia (absolute neutrophil count below 500 cells/mm³) lasting more than 7 days, or febrile neutropenia
- Severe peripheral neuropathy (grade 3 or higher sensory or motor neuropathy)
- Severe mucositis (grade 3 or 4 mouth sores)
- Significant diarrhoea (grade 3 or 4)
- Other severe toxicities as assessed by your oncologist
It is critically important that you inform your doctor about all side effects you experience between cycles, including diarrhoea, mouth sores, numbness, tingling, or fever. This information directly influences dosing decisions. Blood test results are also reviewed before each cycle to ensure your counts have recovered sufficiently.
Method of Administration
Docetaxel Actavis is administered as an intravenous (IV) infusion into a vein over approximately one hour. The concentrate must first be diluted into a compatible infusion solution (5% glucose or 0.9% sodium chloride) by a trained pharmacist or nurse using aseptic technique. The infusion is delivered in a controlled setting where your vital signs, including blood pressure, heart rate, and temperature, are monitored throughout. You will typically remain under observation for a period after the infusion to watch for any immediate hypersensitivity reactions.
What Are the Side Effects of Docetaxel Actavis?
Like all chemotherapy medications, docetaxel can cause side effects, though not everyone experiences all of them. The severity and type of side effects can vary depending on the dose, the specific combination regimen, your overall health, and individual factors. When docetaxel is used in combination with other chemotherapy agents, the severity of side effects may increase due to overlapping toxicities.
During infusion, you will be monitored for allergic reactions, which may include flushing, skin rash, itching, chest tightness, difficulty breathing, fever, chills, back pain, or low blood pressure. More severe anaphylactic reactions can occur but are less common, especially with appropriate corticosteroid premedication. If you have previously had an allergic reaction to paclitaxel, inform your medical team as you may be at higher risk.
Very Common
Affects more than 1 in 10 people
- Infections (due to lowered immune defence)
- Decreased red blood cells (anaemia), white blood cells (neutropenia), and platelets (thrombocytopenia)
- Fever – contact your doctor immediately if you develop fever
- Allergic or hypersensitivity reactions
- Loss of appetite (anorexia)
- Insomnia
- Peripheral neuropathy (numbness, tingling, pain in hands/feet)
- Headache and altered taste
- Eye inflammation, increased tearing
- Fluid retention (lymphoedema, swelling)
- Shortness of breath, runny nose, sore throat, cough, nosebleeds
- Mouth sores (stomatitis), nausea, vomiting, diarrhoea, constipation, stomach pain, indigestion
- Hair loss (usually reversible; rarely permanent)
- Skin reactions: redness and swelling of palms/soles (hand-foot syndrome), skin peeling
- Nail changes and possible nail loss
- Muscle pain, back pain, bone pain
- Menstrual irregularities or absence of menstruation
- Swelling of hands, feet, and legs
- Fatigue, flu-like symptoms, weight changes
- Upper respiratory tract infection
Common
Affects up to 1 in 10 people
- Oral thrush (fungal mouth infection)
- Dehydration
- Dizziness
- Hearing impairment
- Low blood pressure, irregular or rapid heartbeat, high blood pressure
- Heart failure
- Oesophagitis (inflammation of the gullet), dry mouth, difficulty swallowing
- Increased bleeding tendency
- Elevated liver enzymes (detected via blood tests)
- Elevated blood sugar levels (diabetes)
- Decreased potassium, calcium, and/or phosphate levels in the blood
- Skin reactions and vein inflammation at the injection site
Uncommon
Affects up to 1 in 100 people
- Fainting
- Blood clots (thromboembolism)
- Acute myeloid leukaemia or myelodysplastic syndrome (secondary blood cancers) – may occur in patients treated with docetaxel in combination with certain other anticancer agents
Rare / Frequency Not Known
Affects up to 1 in 1,000 people or unknown frequency
- Colitis, enterocolitis (inflammation of the bowel, potentially fatal), intestinal perforation
- Interstitial lung disease (inflammation causing cough and breathing difficulty)
- Pneumonia, pulmonary fibrosis
- Kidney disorders
- Hepatitis (liver inflammation)
- Blurred vision due to retinal swelling (cystoid macular oedema)
- Decreased sodium and/or magnesium levels
- Ventricular arrhythmia or tachycardia (irregular/rapid heartbeat, severe breathlessness, dizziness, fainting)
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- Acute generalised exanthematous pustulosis (AGEP)
- Tumour lysis syndrome (TLS)
- Myositis (muscle inflammation)
- Non-Hodgkin lymphoma (in combination with other anticancer treatments)
- Fever above 38°C (100.4°F), especially with chills or signs of infection
- Severe shortness of breath or difficulty breathing
- Blistering, peeling, or bleeding of the skin or mucous membranes
- Irregular or rapid heartbeat with dizziness or fainting
- Severe abdominal pain, rectal bleeding, or blood in stool
- Dark urine, seizures, or significantly reduced urine output
How Should You Store Docetaxel Actavis?
As Docetaxel Actavis is a hospital-administered medication, storage is managed by your healthcare facility's pharmacy. However, understanding proper storage conditions is important for ensuring the quality and safety of the medicine you receive.
Unopened vials should be stored at or below 25°C (77°F) in the original carton to protect the contents from light. The product must not be refrigerated below 2°C or frozen, as this can compromise the stability of the formulation. Always check the expiry date on the carton and vial before use.
After opening: Each vial is for single use only and should be used immediately after opening. If not used immediately, the diluted infusion solution may be stored for up to 3 days at 2–8°C protected from light, or up to 8 hours (including the one-hour infusion time) at room temperature below 25°C. The diluted solution is supersaturated and may crystallise over time. If crystals appear, the solution must be discarded and not used.
As with all cytotoxic drugs, unused product and all waste materials must be disposed of according to local requirements for hazardous pharmaceutical waste. Docetaxel should never be disposed of via household waste or sewage systems.
What Does Docetaxel Actavis Contain?
Docetaxel Actavis concentrate for solution for infusion is a clear, pale yellow solution supplied in colourless glass vials sealed with a flip-off cap with a bromobutyl rubber stopper and polypropylene disc. The vials may be provided with or without a protective plastic overwrap.
| Component | Role | Details |
|---|---|---|
| Docetaxel | Active ingredient | 20 mg per ml (available as 20 mg/ml and 10 mg/ml concentrations) |
| Citric acid | pH adjuster / buffer | Maintains solution stability |
| Povidone | Solubilising agent | Enhances solubility of docetaxel |
| Absolute ethanol | Co-solvent | ~40% w/v; essential for maintaining docetaxel in solution |
| Polysorbate 80 | Surfactant / emulsifier | Aids solubility; note: hypersensitivity to polysorbate 80 is a contraindication |
Available pack sizes: 1 × 1 ml vial (single dose), 1 × 4 ml vial (single dose), 1 × 7 ml vial (single dose), and 1 × 8 ml vial (single dose). Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Docetaxel Actavis
Docetaxel Actavis is a chemotherapy medication used to treat several types of cancer, including breast cancer (both early-stage and advanced), non-small cell lung cancer, metastatic castration-resistant prostate cancer, gastric (stomach) adenocarcinoma, and squamous cell carcinoma of the head and neck. It may be given as a single agent or in combination with other anticancer drugs depending on the specific indication and stage of disease.
The most frequently reported side effects include neutropenia (low white blood cell count, which increases infection risk), anaemia, hair loss (alopecia), nausea, vomiting, stomatitis (mouth sores), diarrhoea, fatigue, peripheral neuropathy (numbness or tingling in hands and feet), and fluid retention. Hair loss is very common but usually reversible once treatment is completed, though permanent hair loss has been reported in rare cases.
Dexamethasone (a corticosteroid) premedication is mandatory before docetaxel to prevent or reduce the severity of hypersensitivity (allergic) reactions and fluid retention. The standard regimen is dexamethasone 8 mg twice daily for 3 days, beginning 1 day before the infusion. Studies have shown that without corticosteroid premedication, the rates of severe fluid retention and anaphylactic reactions are substantially higher.
The duration of docetaxel treatment varies by cancer type and regimen. Each infusion takes approximately one hour and is typically given once every three weeks. For adjuvant breast cancer (TAC regimen), treatment usually consists of 6 cycles. For advanced cancers, treatment continues as long as there is clinical benefit and the side effects remain manageable. Your oncologist will regularly assess your response and determine the optimal duration of therapy.
No. Docetaxel can cause serious harm to a developing foetus and must not be used during pregnancy unless absolutely necessary as determined by your oncologist. Women of childbearing potential must use reliable contraception during treatment and for at least 2 months after the last dose. Male patients must also use contraception during and for 4 months after treatment. Men should consider sperm banking before beginning therapy, as docetaxel may impair fertility.
Yes, Docetaxel Actavis contains ethanol (approximately 40% w/v). The exact amount depends on the vial size used. This alcohol content may be relevant for patients with a history of alcohol dependence, liver disease, or epilepsy, and for those taking medications that interact with alcohol. The alcohol may also affect the central nervous system and your ability to drive or operate machinery. Discuss any concerns with your healthcare team.
References
- European Medicines Agency (EMA). Docetaxel – Summary of Product Characteristics. Last updated 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. Geneva: WHO; 2023.
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX 327). N Engl J Med. 2004;351(15):1502-1512.
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer (BCIRG 001). N Engl J Med. 2005;352(22):2302-2313.
- Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer (TAX 326). J Clin Oncol. 2003;21(16):3016-3024.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer, NSCLC, Prostate Cancer. Version 2024.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines. Updated 2024.
- British National Formulary (BNF). Docetaxel monograph. Accessed January 2026.
- Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX 323). N Engl J Med. 2007;357(17):1695-1704.
- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer (V325). J Clin Oncol. 2006;24(31):4991-4997.
About Our Medical Editorial Team
This article has been written and reviewed by our medical editorial team, consisting of licensed specialist physicians in oncology, clinical pharmacology, and internal medicine. All content follows the GRADE evidence framework and is based on current international guidelines from ESMO, NCCN, WHO, and EMA.